Clinical trial NCT01555528: To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Mexico
Official title: Easypod Connect: A National, Multicentre, Observational Registry to Evaluate Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using "Easypod™" Electromechanical Device for Growth Hormone Treatment in Mexico
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Growth Disorders
Keywords: Growth disorders
Saizen
Easypod
Growth hormone
Pediatric subject
Lead sponsor: Merck KGaA, Darmstadt, Germany
Sponsor class: INDUSTRY
Collaborators: name: Merck S.A. de C.V., Mexico
First posted: 2012-03-15
Enrollment: 193
Sex: ALL
Minimum age (years): 2
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using the easypod™ electromechanical device.

Brief summary: This is a Mexican, Multicentre, Observational Study to evaluate Adherence and Long Term Outcomes of Therapy in paediatric subjects using easypod™ electromechanical device for growth hormone treatment to assess the level of adherence of subject receiving SAIZEN® via easypod™.

Detailed description: Subjects will be enrolled in a multicenter longitudinal observational study. Parents and patients will provide their Informed Consent to upload their data for population-based analyses and optionally to adhere to a patient adherence support program "AUMENTA" designed to improve their adherence and, ultimately, clinical outcomes. Adherence data will be primarily derived from the easypod™ device combined with physician data entry of outcome measures. Data will be collected retrospectively and prospectively. This will allow the establishment of adherence profiles and explore the hypothesis that patient adherence support programs improve adherence and subsequent clinical outcomes. Collected data will be also analyzed in a multinational pooled analysis of comparable national studies.

Primary Objective:

-To assess the level of adherence of subjects receiving SAIZEN® via easypod™

Secondary Objectives:

* To describe the impact of adherence on clinical outcomes for subject receiving SAIZEN® via easypod™
* To identify adherence subject profiling
* To asses the impact of adherence on IGF1 (i.e. above, below or within normal ranges)
* To assess/describe the impact of Mexico patient support program "AUMENTA"

Eligibility criteria: Inclusion Criteria:

* Administered growth hormone via the easypod™ electromechanical device according to local Prescribing information
* Over the age of \> 2 years
* Under \< 18 years of age, or over 18 without fusion of growth plates
* Parents' or guardian's written informed consent, given before entering data into the observational study, with the understanding that the subject or parents/guardian may withdraw consent at any time without prejudice to future medical care. If the child is old (over 18 without fusion of growth plates) or able to give written informed consent, a separate assent form will be given
* Patient signed informed consent if has 7-17 years old
* Patient signed informed consent if has 18 years old

Exclusion Criteria:

* Subjects taking growth hormone in whom growth plates have fused (i.e. for taking growth hormone for it's metabolic effects)
* Contra-indications to SAIZEN® as defined in the local prescribing information
* Use of an investigational drug or participation in another interventional clinical study

Primary outcomes:
measure: Mean percent of daily recorded adherence
timeFrame: At least 6 months and up to 4 years
Secondary outcomes:
measure: Correlation of adherence and growth outcome after each year of SAIZEN® treatment with easypod™
timeFrame: At least 6 months and up to 4 years
measure: Subject adherence profile based on age, gender, indication, self-injection or not, time on treatment
timeFrame: At least 6 months and up to 4 years
measure: Correlation of adherence with current IGF-1 status (i.e. above, below or within normal ranges)
timeFrame: At least 6 months and up to 4 years
Other outcomes:
Locations:
city: Please Contact The Merck KGaA Communication Center
country: Mexico
facility: For Recruiting Locations in Mexico
Study officials:
affiliation: Merck S.A. de C.V., Mexico, an affiliate of Merck KGaA, Darmstadt,
name: Medical Director
role: STUDY_DIRECTOR
References:
citation: Koledova, E. et al. (2017) Analysis of results from the global, 5-year Easypod™ Connect Observational Study (ECOS) study in children with growth disorders. 10th International Meeting for Pediatric Endocrinology; 2017 Sep 14-17; Washington, DC.
citation: Wit, JM. et al. (2017) Effect of adherence on the 2-year growth response to growth hormone treatment in prepubertal children with idiopathic isolated growth hormone deficiency participating in the EasypodTM Connect Observational Study (ECOS). 10th International Meeting of Paediatric Endocrinology; 2017 Sep 14-17; Washington, DC.